Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Impact of a value-based formulary in three chronic disease cohorts.

Yeung K, Basu A, Marcum ZA, Watkins JB, Sullivan SD.

Am J Manag Care. 2017 Mar;23(3 Suppl):S46-S53. doi: 87035.

PMID:
29648740
2.

Affordability of Health Care: A Global Crisis.

Watkins JB.

Value Health. 2018 Mar;21(3):280-282. doi: 10.1016/j.jval.2018.01.001. Review. No abstract available.

PMID:
29566834
3.

Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.

Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips KA.

Value Health. 2017 Jan;20(1):40-46. doi: 10.1016/j.jval.2016.09.2402.

4.

Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.

Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD.

Med Care. 2017 Feb;55(2):191-198. doi: 10.1097/MLR.0000000000000630.

5.

Dichloroacetate alters Warburg metabolism, inhibits cell growth, and increases the X-ray sensitivity of human A549 and H1299 NSC lung cancer cells.

Allen KT, Chin-Sinex H, DeLuca T, Pomerening JR, Sherer J, Watkins JB 3rd, Foley J, Jesseph JM, Mendonca MS.

Free Radic Biol Med. 2015 Dec;89:263-73. doi: 10.1016/j.freeradbiomed.2015.08.006. Epub 2015 Sep 21.

PMID:
26393423
6.

Design, implementation, and first-year outcomes of a value-based drug formulary.

Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB.

J Manag Care Spec Pharm. 2015 Apr;21(4):269-75.

7.

Improving the usefulness of budget impact analyses: a U.S. payer perspective.

Watkins JB, Danielson D.

Value Health. 2014 Jan-Feb;17(1):3-4. doi: 10.1016/j.jval.2013.09.007. No abstract available.

8.

Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach.

Klein G, Gold LS, Sullivan SD, Buist DS, Ramsey S, Kreizenbeck K, Snell K, Loggers ET, Gifford J, Watkins JB, Kessler L.

J Comp Eff Res. 2012 May;1(3):241-55.

9.

Creating models that meet decision makers' needs: a US payer perspective.

Watkins JB.

Value Health. 2012 Sep-Oct;15(6):792-3. doi: 10.1016/j.jval.2012.03.1386. No abstract available.

10.

Can CER be an effective tool for change in the development and assessment of new drugs and technologies?

Brixner DI, Watkins JB.

J Manag Care Pharm. 2012 Jun;18(5 Supp A):S06-11.

PMID:
22663293
11.

Payer perspectives on health technology assessment.

Watkins JB.

J Manag Care Pharm. 2012 Apr;18(3):265-7. No abstract available.

12.

Acceleration of the meckel syndrome by near-infrared light therapy.

Lim J, Gattone VH 2nd, Sinders R, Miller CA, Liang Y, Harris P, Watkins JB 3rd, Henshel DS.

Nephron Extra. 2011 Jan;1(1):224-34. doi: 10.1159/000332046. Epub 2011 Nov 25.

13.

Effects of low-level light therapy on streptozotocin-induced diabetic kidney.

Lim J, Sanders RA, Snyder AC, Eells JT, Henshel DS, Watkins JB 3rd.

J Photochem Photobiol B. 2010 May 3;99(2):105-10. doi: 10.1016/j.jphotobiol.2010.03.002. Epub 2010 Mar 11.

PMID:
20356759
14.

Standardizing quality assessment of observational studies for decision making in health care.

Brixner DI, Holtorf AP, Neumann PJ, Malone DC, Watkins JB.

J Manag Care Pharm. 2009 Apr;15(3):275-83. No abstract available.

15.

Presentation of the 2008 Murray Davidson Award to Jay A. Perman, MD.

Watkins JB.

J Pediatr Gastroenterol Nutr. 2009 Mar;48(3):247-8. No abstract available.

PMID:
19274802
16.

The payer's dilemma: recognizing the uncertainty of clinical and economic evidence at product launch.

Watkins JB, Sullivan SD.

J Manag Care Pharm. 2009 Mar;15(2):167-70. No abstract available.

17.

Effects of low-level light therapy on hepatic antioxidant defense in acute and chronic diabetic rats.

Lim J, Ali ZM, Sanders RA, Snyder AC, Eells JT, Henshel DS, Watkins JB 3rd.

J Biochem Mol Toxicol. 2009 Jan-Feb;23(1):1-8. doi: 10.1002/jbt.20257.

PMID:
19202557
18.

Attenuation of TCDD-induced oxidative stress by 670 nm photobiomodulation in developmental chicken kidney.

Lim J, Sanders RA, Yeager RL, Millsap DS, Watkins JB 3rd, Eells JT, Henshel DS.

J Biochem Mol Toxicol. 2008 Jul-Aug;22(4):230-9. doi: 10.1002/jbt.20233.

PMID:
18752309
19.

Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion.

Holtorf AP, Watkins JB, Mullins CD, Brixner D.

J Manag Care Pharm. 2008 Apr;14(3):302-8. No abstract available.

20.

Melatonin as a principal component of red light therapy.

Yeager RL, Oleske DA, Sanders RA, Watkins JB 3rd, Eells JT, Henshel DS.

Med Hypotheses. 2007;69(2):372-6. Epub 2007 Feb 23.

PMID:
17321060
21.

Suppression of endogenous antioxidant enzymes by 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced oxidative stress in chicken liver during development.

Lim J, DeWitt JC, Sanders RA, Watkins JB 3rd, Henshel DS.

Arch Environ Contam Toxicol. 2007 May;52(4):590-5. Epub 2007 Feb 5.

PMID:
17285237
22.

Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.

Watkins JB, Minshall ME, Sullivan SD.

J Manag Care Pharm. 2006 Nov-Dec;12(9):726-35.

23.

670 nanometer light treatment attenuates dioxin toxicity in the developing chick embryo.

Yeager RL, Lim J, Millsap DS, Jasevicius AV, Sanders RA, Whelan HT, Watkins JB 3rd, Eells JT, Henshel DS.

J Biochem Mol Toxicol. 2006;20(6):271-8.

PMID:
17163486
24.

Low-carbohydrate diet and oxidative stress in diabetic and nondiabetic rats.

Kamuren ZT, Sanders R, Watkins JB 3rd.

J Biochem Mol Toxicol. 2006;20(5):259-69.

PMID:
17009256
25.

Managing biotechnology in a network-model health plan: a U.S. private payer perspective.

Watkins JB, Choudhury SR, Wong E, Sullivan SD.

Health Aff (Millwood). 2006 Sep-Oct;25(5):1347-52.

PMID:
16966732
26.

Effects of low-carbohydrate diet and Pycnogenol treatment on retinal antioxidant enzymes in normal and diabetic rats.

Kamuren ZT, McPeek CG, Sanders RA, Watkins JB 3rd.

J Ocul Pharmacol Ther. 2006 Feb;22(1):10-8.

PMID:
16503770
27.

Effects of antioxidant treatment on normal and diabetic rat retinal enzyme activities.

Dene BA, Maritim AC, Sanders RA, Watkins JB 3rd.

J Ocul Pharmacol Ther. 2005 Feb;21(1):28-35.

PMID:
15718825
28.

Influence of treatment of diabetic rats with combinations of pycnogenol, beta-carotene, and alpha-lipoic acid on parameters of oxidative stress.

Berryman AM, Maritim AC, Sanders RA, Watkins JB 3rd.

J Biochem Mol Toxicol. 2004;18(6):345-52.

PMID:
15674846
29.

Evaluating metabolic syndrome in a medical physiology laboratory.

Martin B, Watkins JB 3rd, Ramsey JW.

Adv Physiol Educ. 2004 Dec;28(1-4):195-8.

30.

Oxidative stress in rats after 60 days of hypergalactosemia or hyperglycemia.

Otsyula M, King MS, Ketcham TG, Sanders RA, Watkins JB 3rd.

Int J Toxicol. 2003 Nov-Dec;22(6):423-7.

PMID:
14680989
31.

Effects of alpha-lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetic rats.

Maritim AC, Sanders RA, Watkins JB 3rd.

J Nutr Biochem. 2003 May;14(5):288-94.

PMID:
12832033
32.

Effects of pycnogenol treatment on oxidative stress in streptozotocin-induced diabetic rats.

Maritim A, Dene BA, Sanders RA, Watkins JB 3rd.

J Biochem Mol Toxicol. 2003;17(3):193-9.

PMID:
12815616
33.

The role of pharmacoeconomic modeling in depression management by a health plan.

Watkins JB.

Manag Care Interface. 2003;Suppl B:22-6. No abstract available.

PMID:
12647610
34.

Diabetes, oxidative stress, and antioxidants: a review.

Maritim AC, Sanders RA, Watkins JB 3rd.

J Biochem Mol Toxicol. 2003;17(1):24-38. Review.

PMID:
12616644
35.

Characterization of oxidative stress in various tissues of diabetic and galactose-fed rats.

Strother RM, Thomas TG, Otsyula M, Sanders RA, Watkins JB 3rd.

Int J Exp Diabetes Res. 2001;2(3):211-6.

36.

Effects of beta-carotene on oxidative stress in normal and diabetic rats.

Maritim A, Dene BA, Sanders RA, Watkins JB 3rd.

J Biochem Mol Toxicol. 2002;16(4):203-8.

PMID:
12242690
37.

Effects of combined quercetin and coenzyme Q(10) treatment on oxidative stress in normal and diabetic rats.

Coldiron AD Jr, Sanders RA, Watkins JB 3rd.

J Biochem Mol Toxicol. 2002;16(4):197-202.

PMID:
12242689
38.

Effects of isoeugenol on oxidative stress pathways in normal and streptozotocin-induced diabetic rats.

Rauscher FM, Sanders RA, Watkins JB 3rd.

J Biochem Mol Toxicol. 2001;15(3):159-64.

PMID:
11424226
39.

Effects of quercetin on antioxidant defense in streptozotocin-induced diabetic rats.

Sanders RA, Rauscher FM, Watkins JB 3rd.

J Biochem Mol Toxicol. 2001;15(3):143-9.

PMID:
11424224
40.

Changes in the kinetic parameters of hepatic gamma-glutamyltransferase from streptozotocin-induced diabetic rats.

Cornwell PD, Watkins JB 3rd.

Biochim Biophys Acta. 2001 Feb 9;1545(1-2):184-91.

PMID:
11342044
41.

Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats.

Rauscher FM, Sanders RA, Watkins JB 3rd.

J Biochem Mol Toxicol. 2001;15(1):41-6.

PMID:
11170314
42.

Effects of piperine on antioxidant pathways in tissues from normal and streptozotocin-induced diabetic rats.

Rauscher FM, Sanders RA, Watkins JB 3rd.

J Biochem Mol Toxicol. 2000;14(6):329-34.

PMID:
11083086
43.

Effects of new antioxidant compounds PNU-104067F and PNU-74389G on antioxidant defense in normal and diabetic rats.

Rauscher FM, Sanders RA, Watkins JB 3rd.

J Biochem Mol Toxicol. 2000;14(4):189-94.

PMID:
10789496
44.

Effects of aldose reductase inhibitors on antioxidant defense in rat and rabbit liver.

Thomas T, Rauscher F, Sanders R, Veltman J, Watkins JB 3rd.

Toxicol Sci. 2000 Jan;53(1):145-9.

PMID:
10653532
45.

Decreased apoptosis as a mechanism for hepatomegaly in streptozotocin-induced diabetic rats.

Herrman CE, Sanders RA, Klaunig JE, Schwarz LR, Watkins JB 3rd.

Toxicol Sci. 1999 Jul;50(1):146-51.

PMID:
10445763
46.

Venipuncture in the medical physiology laboratory.

Martin BJ, Watkins JB 3rd, Ramsey J.

Am J Physiol. 1998 Jun;274(6 Pt 2):S62-7.

PMID:
9841567
47.

Streptozotocin-induced diabetes increases gamma-glutamyltranspeptidase activity but not expression in rat liver.

Watkins JB 3rd, Klaunig JE, Smith HM, Cornwell P, Sanders RA.

J Biochem Mol Toxicol. 1998;12(4):219-25.

PMID:
9580874
48.

Streptozotocin may provide protection against subsequent oxidative stress of endotoxin or streptozotocin in rats.

Omar HM, Rosenblum JK, Sanders RA, Watkins JB 3rd.

J Biochem Mol Toxicol. 1998;12(3):143-9.

PMID:
9522273
49.

Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone.

Isenberg JS, Kolaja KL, Ayoubi SA, Watkins JB 3rd, Klaunig JE.

Carcinogenesis. 1997 Aug;18(8):1511-9.

PMID:
9276624
50.

Hepatobiliary excretion of bile acids and rose bengal in streptozotocin-induced and genetic diabetic rats.

Stone JL, Braunstein JB, Beaty TM, Sanders RA, Watkins JB 3rd.

J Pharmacol Exp Ther. 1997 Apr;281(1):412-9.

Supplemental Content

Loading ...
Support Center